Hepatopancreatobiliary Surgery Institute of Gansu Province
Phase
Not applicable
Started
2026-04-01
Last updated
2025-12-26
Condition(s) studied
Cholangitis
Investigational drug(s) / intervention(s)
Injection of 37℃ contrast agent
Injection of 37℃ contrast agent: Nonionic contrast agent is heated to 37℃ in a incubator when injection of contrast agent
Study summary
The purpose of this study is to determine the effect of normal temperature and 37℃ non-ionic contrast agent acting on ERCP-related cholangeitis after endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of hilar cholangiocarcinoma.
Eligibility
Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria:
* Type Ⅰ、Ⅱ、Ⅲ、Ⅳ of Hilar Cholangiocarcinoma;
* Age: 18\~90 years old;
* Underwent diagnostic and therapeutic ERCP;
Exclusion Criteria:
* Coagulation dysfunction(INR\>1.3) or/and low peripheral blood platelet count （PLT \<50x10\^9/L）;
* Preoperative acute cholangitis;
* Preoperative acute pancreatitis;
* Preoperative hemobilia or hemorrhage of digestive tract;
* Preoperative liver failure;
* Combined with Mirizzi syndrome and intrahepatic bile duct stones;
* Preoperative malignant tumor of biliary system such as carcinoma of head of pancreas, gallbladder carcinoma;
* Biliary-duodenal fistula confirmed during ERCP;
* A history of reconstructive surgery for upper digestive tract except Billroth Ⅰand a history of cholangioenterostomy including cholangio-jejunostomy and side to side anastomosis of the bile duct and duodenum;
* Previous ERCP;
* Pregnant women
Primary outcome measure(s)
Number of participants with Acute cholangitis — 2 weeks Acute cholangitis is defined if patients experienced abdominal pain, high fever(over 38.5℃), or chill after procedure in 2 weeks
Trial sites (3)
Facility
City
Region
Status
The first hospital of Lanzhou university
Lanzhou
Gansu
The first affiliated hospital of Xi 'an jiaotong university
Xi'an
Shaanxi
Tianjin Nankai Hospital
Tianjin
Tianjin Municipality
More Hepatopancreatobiliary Surgery Institute of Gansu Province trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.